Evidence map›Paper›PMID 22027492›Full record

ArticleJournal of neuroscience methods2012

Use of vivo-morpholinos for control of protein expression in the adult rat brain.

Kathryn J Reissner, Gregory C Sartor, Elena M Vazey, Thomas E Dunn, Gary Aston-Jones, Peter W Kalivas

Abstract read
In one paragraph

Article in Journal of neuroscience methods, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 50 citations in OpenAlex.

  1. The neuroimmune-glutamate hypothesis of addiction.Neuroscience and biobehavioral reviews · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Pharmacokinetics and Proceedings in Clinical Application of Nucleic Acid Therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Review
  12. Extrahypothalamic oxytocin neurons drive stress-induced social vigilance and avoidance.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Knockdown of hypocretin attenuates extended access of cocaine self-administration in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kathryn J ReissnerDepartment of Neurosciences, Medical University of South Carolina, Charleston, SC 29425, USA. reissner@musc.edu
Gregory C Sartor
Elena M Vazey
Thomas E Dunn
Gary Aston-Jones
Peter W Kalivas
Medical University of South Carolina · US

Funding

Selective Restoration of KCNQ Channel Inhibition in the PFC to Inhibit Cue-InducP50DA015369 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KALIVAS, PETER W · 2003 to 2017
$18.6M
DRUG ABUSE TRAINING PROGRAMT32DA007288 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Christopher W Cowan, Rachel Penrod-Martin · 1991 to 2026
$11.8M
GLUTAMATE AND CRAVING FOR COCAINER01DA012513 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KALIVAS, PETER W · 2000 to 2024
$7.5M
ROLE OF OREXIN IN COCAINE DEMAND AND ADDICTIONR01DA006214 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI ASTON-JONES, GARY S. · 1989 to 2024
$6.0M
Role of Extended Amygdala in Opiate and Cocaine AbuseR37DA006214 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI ASTON-JONES, GARY S. · 2003 to 2012
$4.2M
OPIOIDS, AMPHETAMINE &COCAIN IN DRUG ABUSER01DA003906 · NIDA · WASHINGTON STATE UNIVERSITY · PI KALIVAS, PETER W · 1985 to 2019
$3.6M
COCAINE, OPIOIDS AND DRUG ABUSER37DA003906 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KALIVAS, PETER W · 2000 to 2009
$3.0M
Cytoskeletal Mechanisms of Cocaine-Induced NeuroplasticityF32DA026254 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI REISSNER, KATHRYN JOANNA · 2009 to 2011
$157k
NIDA NIH HHS DA003906NIDA NIH HHS DA007288NIDA NIH HHS DA015369NIDA NIH HHS DA026254NIDA NIH HHS DA06214NIDA NIH HHS F32 DA026254NIDA NIH HHS P50 DA015369NIDA NIH HHS R01 DA003906NIDA NIH HHS R01 DA006214NIDA NIH HHS R01 DA012513NIDA NIH HHS R37 DA003906NIDA NIH HHS R37 DA006214NIDA NIH HHS T32 DA007288
6 · The paper itself

Abstract

Vivo-morpholinos are commercially available morpholino oligomers with a terminal octa-guanidinium dendrimer for enhanced cell-permeability. Existing evidence from systemically delivered vivo-morpholinos indicate that genetic suppression can last from days to weeks without evidence of cellular toxicity. However, intravenously delivered vivo-morpholinos are ineffective at protein suppression in the brain, and no evidence is available regarding whether intracranially delivered vivo-morpholinos effectively reduce target protein levels, or do so without inducing neurotoxicity. Here we report examples in which in vivo microinjection of antisense vivo-morpholinos directed against three different targets (xCT, GLT1, orexin) in two different brain regions resulted in significant suppression of protein expression without neurotoxicity. Expression was significantly suppressed at six to seven days post-administration, but returned to baseline levels within fourteen days. These results indicate that direct intracranial administration of vivo-morpholinos provides an effective means by which to suppress protein expression in the brain for one to two weeks.

Indexed as

AnimalsAntisense Elements (Genetics)BrainMaleMicroinjectionsMorpholinosNerve Tissue ProteinsProteomicsRatsRats, Sprague-DawleyRNA, MessengerAntisense Elements (Genetics)MorpholinosNerve Tissue ProteinsRNA, Messenger

Identifiers

PMID22027492
PMCPMC3857614
OpenAlexW2027782787

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.